Major Shareholder Group Exits Entire 43.79% Stake in CDT Equity, Selling Over $2.98M in Shares
CDT sits 70% above its 52-week low of $0.671.
Summary
A major investor group, Mark Taylor and associated entities, has fully exited its 43.79% stake in CDT Equity Inc., selling over $2.98 million worth of shares, which is more than half of the company's market cap.
Key Events · Ownership and Investor Activity · CDT
-
Major Shareholder Exit
The Mark Taylor-led investor group, which previously held a 43.79% beneficial ownership, has fully liquidated its entire stake in CDT Equity Inc.
-
Significant Share Sale
The group sold a total of 2,068,000 shares for approximately $2.98 million on June 18, 2026. This represents over 50% of the company's current market capitalization.
-
Timing with Positive News
The liquidation occurred on the same day the company announced a $127.5 million valuation for its stake in Sarborg Limited, potentially indicating the group sold into market strength.
-
Impact on Ownership Structure
The reporting persons (Mark Taylor, Prospect Capital Securities Ltd, and Prospect Finance Ltd) no longer beneficially own more than 5% of the outstanding common stock.
Analysis · CDT · Life Sciences
An investor group led by Mark Taylor, which previously held a significant 43.79% stake in CDT Equity Inc., has fully liquidated its position. The group sold a total of 2,068,000 shares for approximately $2.98 million, representing over 50% of the company's current market capitalization. This complete exit by a major shareholder group is a strong negative signal, particularly given the company's ongoing financial challenges, including a going concern warning and Nasdaq deficiency. The sales occurred on the same day as a positive news release regarding an investment valuation, suggesting the group may have capitalized on a temporary uplift to facilitate their exit.
How filings like this one have moved
In the 30 days to Oct 25, 2026, 45.9% of the 259 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.67%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.67 to $610.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.